Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $18.2 million.

  • Biodesix's Total Current Liabilities rose 40.03% to $18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year increase of 40.03%. This contributed to the annual value of $14.3 million for FY2024, which is 57.16% down from last year.
  • Biodesix's Total Current Liabilities amounted to $18.2 million in Q3 2025, which was up 19.74% from $15.2 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Total Current Liabilities peaked at $37.4 million during Q3 2022, and registered a low of $13.0 million during Q3 2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $18.2 million (2025), whereas its average is $21.7 million.
  • As far as peak fluctuations go, Biodesix's Total Current Liabilities soared by 84.89% in 2022, and later tumbled by 60.30% in 2024.
  • Biodesix's Total Current Liabilities (Quarterly) stood at $29.0 million in 2021, then declined by 21.14% to $22.8 million in 2022, then soared by 46.31% to $33.4 million in 2023, then crashed by 57.16% to $14.3 million in 2024, then spiked by 40.03% to $18.2 million in 2025.
  • Its last three reported values are $18.2 million in Q3 2025, $15.2 million for Q2 2025, and $13.3 million during Q1 2025.